The Correlation Between Biological Markers and Prognosis in Thyroid Cancer
Rami Hajjar, Ciprian Duta, Ionut Flaviu Faur, Catalin Prodan-Barbulescu, Hadi Alhajjar, Stelian Pantea, Christos K Kontos · 2024
Read The Correlation Between Biological Markers and Prognosis in Thyroid Cancer by Rami Hajjar, Ciprian Duta, Ionut Flaviu Faur, Catalin Prodan-Barbulescu, Hadi Alhajjar, Stelian Pantea, Christos K Kontos (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11673981.txt.
Description
Thyroid cancer is rising worldwide, and doctors want blood markers that warn which patients face a rougher course. Rami Hajjar and co-authors test three candidates in a 2024 study of 395 patients treated over eight years. The markers are the BRAF V600E mutation and the proteins thyroglobulin and calcitonin.
Patients carrying the mutation were older, arrived at later stages, and ran higher marker levels, with thyroglobulin roughly doubling from stage one to stage four. Patients below set marker thresholds enjoyed markedly better five-year survival, 82 against 68 percent. Age, stage, and high markers each independently predicted death. The authors argue the trio can flag patients who need closer watching after surgery.
Catalog record
| CREATOR | Rami Hajjar, Ciprian Duta, Ionut Flaviu Faur, Catalin Prodan-Barbulescu, Hadi Alhajjar, Stelian Pantea, Christos K Kontos |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |